WESTLAKE VILLAGE, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in three upcoming investor conferences. Details for the company’s participation are as follows:
|
Citi’s 2025 Biopharma Back to School Conference, September 2-3, 2025 |
|
| Fireside Chat Date: Wednesday, September 3, 2025 | |
| Fireside Chat Time: 9:45 am EDT | |
|
Morgan Stanley’s 23rd Annual Global Healthcare Conference, September 8-10, 2025 |
|
| Fireside Chat Date: Tuesday, September 9, 2025 | |
| Fireside Chat Time: 2:35pm EDT | |
|
HC Wainwright 27th Annual Global Investment Conference, September 8-10, 2025 |
|
| Fireside Chat Date: Wednesday, September 10, 2025 | |
| Fireside Chat Time: 10:30am EDT | |
Webcasts for these conferences may be accessed at the “Events” section of the Company’s website. A replay of these webcasts will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to invent differentiated therapies against biologically validated targets, and has produced a robust pipeline for inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations and are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
[email protected]
Investors
Brian Schoelkopf
[email protected]
